article
Is There Genetic Polymorphism Evidence for Individual Human Sensitivity to Opiates?
Current Pain and Headache Reports 2007, 11:115-123
Makoto Nagashima, MD, PhD, Ryoji Katoh, MD, PhD, Yasuo Sato, MD,
Megumi Tagami, MD, PhD, Shinya Kasai, PhD, and Kazutaka Ikeda, PhD
Corresponding author: Kazutaka Ikeda, PhD, Department of Molecular
Psychiatry, Tokyo Institute of Psychiatry, 2-1-8 Kamikitazawa,
Setagaya-ku, Tokyo 156-8585, Japan. Email: ikedak@prit.go.jp
Opiate analgesics have been widely used for severe acute pain and
chronic cancer-related pain. Individual differences in the
effectiveness of opiates and their side effects limit the clinical
benefits and increase risks of drug abuse.
Genetic factors might affect variations of opiate sensitivity. The
mu opioid peptide receptor (MOP) is the principal site of
pharmacologic actions for most clinically important opiate drugs.
Recent studies using various knockout mice and recombinant-inbred
strain CXBK mice have indicated that the analgesic effect of morphine
is dependent on the amount of the MOP.
There are more than 100 polymorphisms identified in the human MOP
(OPRM1) gene. These polymorphisms might be correlated with OPRM1 mRNA
stability and opiate sensitivity, including opiate analgesia,
tolerance, and dependence.
More precise studies on the relationship between gene polymorphisms
and opiate sensitivity will enable realization of personalized pain
treatment by predicting opiate sensitivity and requirement for each
patient.
Copyright © 2007 by Current Science, Inc.
Current Pain and Headache Reports 2007, 11:115-123
Makoto Nagashima, MD, PhD, Ryoji Katoh, MD, PhD, Yasuo Sato, MD,
Megumi Tagami, MD, PhD, Shinya Kasai, PhD, and Kazutaka Ikeda, PhD
Corresponding author: Kazutaka Ikeda, PhD, Department of Molecular
Psychiatry, Tokyo Institute of Psychiatry, 2-1-8 Kamikitazawa,
Setagaya-ku, Tokyo 156-8585, Japan. Email: ikedak@prit.go.jp
Opiate analgesics have been widely used for severe acute pain and
chronic cancer-related pain. Individual differences in the
effectiveness of opiates and their side effects limit the clinical
benefits and increase risks of drug abuse.
Genetic factors might affect variations of opiate sensitivity. The
mu opioid peptide receptor (MOP) is the principal site of
pharmacologic actions for most clinically important opiate drugs.
Recent studies using various knockout mice and recombinant-inbred
strain CXBK mice have indicated that the analgesic effect of morphine
is dependent on the amount of the MOP.
There are more than 100 polymorphisms identified in the human MOP
(OPRM1) gene. These polymorphisms might be correlated with OPRM1 mRNA
stability and opiate sensitivity, including opiate analgesia,
tolerance, and dependence.
More precise studies on the relationship between gene polymorphisms
and opiate sensitivity will enable realization of personalized pain
treatment by predicting opiate sensitivity and requirement for each
patient.
Copyright © 2007 by Current Science, Inc.